'New Technologies to Capture Over 10% of the Antibody Therapeutics Market by ... EIN News (press release) You can see Roche getting in on the ground floor there with what they're doing with obinituzumab and T-DM1, using engineering and ADC technologies to extend their rituximab and trastuzumab franchises. T-DM1 is potentially a major watershed for the ... |
